KR910000714A - 항진균성 4[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1h-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론 - Google Patents

항진균성 4[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1h-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론 Download PDF

Info

Publication number
KR910000714A
KR910000714A KR1019900007765A KR900007765A KR910000714A KR 910000714 A KR910000714 A KR 910000714A KR 1019900007765 A KR1019900007765 A KR 1019900007765A KR 900007765 A KR900007765 A KR 900007765A KR 910000714 A KR910000714 A KR 910000714A
Authority
KR
South Korea
Prior art keywords
formula
compound
structural formula
phenyl
following structural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019900007765A
Other languages
English (en)
Other versions
KR0163034B1 (ko
Inventor
하아레스 쟌
쟈코부스 죠세프 박크스 레오
Original Assignee
구스타프 반 리이트
쟈안센 파아마슈우티카 엔. 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 구스타프 반 리이트, 쟈안센 파아마슈우티카 엔. 브이 filed Critical 구스타프 반 리이트
Publication of KR910000714A publication Critical patent/KR910000714A/ko
Application granted granted Critical
Publication of KR0163034B1 publication Critical patent/KR0163034B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음

Description

항진균성4[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1H-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 구조식(Ⅰ)의 화합물과 약제학적으로 허용되는 이들의 산부가염 또는 입체화학적 이성체
    위의 식에서 Q는 CH또는 N이고, Y는 하기구조식의 라디칼이다.
    (위의 식에서 R1은 C5-7시클로알킬 또는 모노-, 디-, 트리-, 테트라- 또는 펜타할로 C1-4알킬이고, R2는 C1-4알킬, C5-7시클로알킬 또는 모노-, 디-, 드리-, 테트라- 또는 펜타할로 C1-4알킬이다)
  2. 제1항에 있어서,Q는 N이고, 디옥솔란 핵에 있는 치환기들이 시스배열을 가진 화합물.
  3. 제2항에 있어서,R1과 R2는 모노-, 디-, 트리-, 테트라- 또는 펜타할로 C1-4알킬, 시클로헥실 또는 시클로펜틸이거나 R2는 C1-4알킬인 화합물.
  4. 제3항에 있어서, R1과 R2는 2.2.2-트리플루오로에틸, 2.2.3.3-테트라플루오로프로필, 시클로펜틸이거나 R2가 프로필, 1-메틸프로필, 2-메틸프로릴 또는 부틸인 화합물.
  5. 제1항에 있어서 화합물이 시스-2-시클로펜틸-4-[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1H-1,2,4-트리아졸-1-일메틸)-1,3-디옥솔린-4-일]메톡시]페닐]-1-피페라지닐]페닐]-2,4-디히드로-3H-1,2,4-트리아졸-3-온, 시스-4-[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1H-1,2,4-트리아졸-1-일메틸)-1,3-디옥솔린-4-일]메톡시]페닐]-1-피페라지닐]페닐]-2,4-디히드로-2-(2,2,2-트리플루오로에틸)-3H-1,2,4-트리아졸-3-온, 또는 시스-1-[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1H-1,2,4-트리아졸-1-일메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]-1,3-디히드로-3-(1-메틸프로필)-2H-이미다졸-2-온인 화합물.
  6. 비활성 담체와 활성성분으로서 제1항 내지 제5항중 어느 한 항에 의한 화합물을 항진균 유효량으로 하여 함유한 항진균성 조성물.
  7. 제1항 내지 제5항 중 어느 한 항에 의한 화합물을 항진균유효량으로 하여 온혈동물에 전신투여 또는 국소투여함으로서 균류에 의한 각종 질환을 앓고 있는 온형동물에 있어서 균류의 생장이나 발육을 억제 또는 예방하거나 균류를 박멸하는 방법.
  8. (a) 반응비활성 용매중에서 염기존재하에 하기 구조식(Ⅲ)의 페놀을 구조식 D-CH2-W(Ⅱ)(여기서 W는 반응성 이탈기)의 알킬화 제로 0-알킬화하거나,
    (b) 반응비활성용매중에서 산 존재하에 하기 구조식(Ⅳ)의 케톤을 구조식(Ⅴ)의 2,3-디히드록시프로필에테르 유도체로 아세탈화 반응시키거나,
    (c) 반응비활성용매중에서 염기존재하에 하기 구조식(Ⅵ)의 아졸 또는 그 금속염을 하기 구조식(Ⅶ)의 중간체로 N-알킬화하거나,
    (위의 식에서 w는 반응성 이탈기이다)
    (d)극성의 반응비활성 용매중에서 하기 구조식(Ⅷ)또는 (Ⅸ)의 중간체를 하기구조식(Ⅸ)또는 (Ⅹ)의 벤젠아민으로 폐환시키거나,
    (위의 식에서 w는 각각 반응성 이탈기이다)
    (e) 반응비활성 용매중에서 염기존재하에 하기 구조식(ⅩⅡ) 또는 (ⅩⅤ)의 피페라진을 하기 구조식(ⅩⅢ)또는 (ⅩⅣ)의 벤젠유도체로 N-알킬화하거나
    (위의 식에서 w′는 반응성 이탈기이다)
    (f) 반응비활성용매중에서 하기 구조식(ⅩⅥ)의 벤젠아민을 하기 구조식(ⅩⅦ)의 시약으로 폐환시켜 하기 구조식(I-a)의 화합물을 얻거나,
    (위의 식에서 L1과 L2는 모두 반응성 이탈기이다)
    (g) 반응비활성 용매중에서 하기 구조식(ⅩⅥ)의 벤젠아민을 하기 구조식(ⅩⅧ)의 시약으로 폐환시켜 하기 구조식(I-b)의 화합물을 얻거나,
    (위의 식에서 L1과 L2는 모두 반응성 이탈기이다)
    (h) 하기 구조식(ⅩⅨ)의 중간체를 구조식 HC(=NH)NH2(ⅩⅩ)의 아미딘으로 폐환시키고 여기서 수득한 중간체를 구조식 R1-W(ⅩⅩⅠ)(여기서 w는 반응성이탈기)의 시약으로 반응비활성용매중에서 N-알킬화하여 하기 구조식(Ⅰ-a)의 화합물을 얻거나
    (i) 반응비활성 용매중에서 산 존재하에 하기 구조식(ⅩⅩⅡ)의 중간체를 구조식 (L2)2-CH-CH2-NHR2(ⅩⅩⅢ)의 시약으로 폐환시키고.
    (위의 식들에 있어서 L1과 L2는 반응성 이탈기이고, D는
    필요에 따라서는 구조식(Ⅰ)의 화합물을 약제학적으로 허용되는 산으로 처리하여 염형태로 전환시키거나, 역으로는 염을 알칼리로 처리하여 유리염기로 전환시키며/또는 그 입체화학적 이성체를 제조함을 특징으로 하는 제1항 내지 제5항중 어느 한 항에 의한 구조식(Ⅰ)의 화합물의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900007765A 1989-06-09 1990-05-29 항진균성 4-[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1h-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론 Expired - Fee Related KR0163034B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36379589A 1989-06-09 1989-06-09
US07363795 1989-06-09
BE363,795 1989-06-09

Publications (2)

Publication Number Publication Date
KR910000714A true KR910000714A (ko) 1991-01-30
KR0163034B1 KR0163034B1 (ko) 1998-12-01

Family

ID=23431765

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007765A Expired - Fee Related KR0163034B1 (ko) 1989-06-09 1990-05-29 항진균성 4-[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1h-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론

Country Status (20)

Country Link
EP (1) EP0402989B1 (ko)
JP (1) JP2988689B2 (ko)
KR (1) KR0163034B1 (ko)
CN (1) CN1025193C (ko)
AT (1) ATE136305T1 (ko)
AU (1) AU624515B2 (ko)
CA (1) CA2018442C (ko)
DE (1) DE69026311T2 (ko)
DK (1) DK0402989T3 (ko)
ES (1) ES2087886T3 (ko)
FI (1) FI96031C (ko)
GR (1) GR3019686T3 (ko)
HU (1) HU215602B (ko)
IE (1) IE71196B1 (ko)
IL (1) IL94660A (ko)
NO (1) NO175477C (ko)
NZ (1) NZ233502A (ko)
PT (1) PT94320B (ko)
RU (1) RU2056421C1 (ko)
ZA (1) ZA904458B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US5464610A (en) * 1992-10-15 1995-11-07 Schering-Plough Healthcare Products, Inc. Method for treating onychomycosis
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
WO1998034934A1 (en) * 1997-02-11 1998-08-13 Janssen Pharmaceutica N.V. Amino acid ester containing azole antifungals
TW593312B (en) 1997-07-11 2004-06-21 Janssen Pharmaceutica Nv 2,4,4-trisubstituted-1,3-dioxolane antifungals
KR100342383B1 (ko) * 1999-06-17 2002-12-06 한국화학연구원 이소옥사졸리딘 유도체, 그의 제조 방법 및 그를 포함하는 살균제 조성물
WO2001007643A1 (en) * 1999-07-28 2001-02-01 Kaken Pharmaceutical Co., Ltd. Method for detecting pathogenic microorganism and antimicrobial agent, method for evaluating the drug effect of antimicrobial agent, and antimicrobial agents
RU2173994C1 (ru) * 2000-12-18 2001-09-27 Д-Р Редди'С Лабораторис Лтд. Лекарственное средство, содержащее флуконазол и способ получения флуконазола
RU2265844C1 (ru) * 2004-05-26 2005-12-10 Волгоградский научно-исследовательский противочумный институт Способ обнаружения возбудителя кокцидиоидомикоза
CN1706834B (zh) * 2004-06-11 2010-04-28 横店集团成都分子实验室有限公司 具抗真菌活性的三唑醇类新衍生物及制备方法和医药用途
CN102234267A (zh) * 2010-04-21 2011-11-09 中国科学院上海药物研究所 新型三氮唑类抗真菌化合物、其药物组合物及其制备方法和用途
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法
CN107455342B (zh) * 2017-08-22 2020-03-10 沧州市农林科学院 三唑酮在提高资源昆虫成活率和/或体重中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions

Also Published As

Publication number Publication date
IL94660A (en) 1995-07-31
IE902072L (en) 1990-12-09
CA2018442A1 (en) 1990-12-09
HU903767D0 (en) 1990-11-28
JP2988689B2 (ja) 1999-12-13
NO902553D0 (no) 1990-06-08
FI96031C (fi) 1996-04-25
EP0402989A3 (en) 1992-01-02
NO175477B (no) 1994-07-11
IE71196B1 (en) 1997-02-12
FI96031B (fi) 1996-01-15
AU624515B2 (en) 1992-06-11
DE69026311D1 (de) 1996-05-09
DE69026311T2 (de) 1996-09-05
IL94660A0 (en) 1991-04-15
KR0163034B1 (ko) 1998-12-01
HUT58325A (en) 1992-02-28
DK0402989T3 (da) 1996-05-06
NZ233502A (en) 1991-11-26
HU215602B (hu) 1999-01-28
FI902882A0 (fi) 1990-06-08
EP0402989A2 (en) 1990-12-19
NO902553L (no) 1990-12-10
PT94320A (pt) 1991-02-08
CA2018442C (en) 2002-02-12
PT94320B (pt) 1996-12-31
ES2087886T3 (es) 1996-08-01
JPH03163077A (ja) 1991-07-15
NO175477C (no) 1994-10-19
ZA904458B (en) 1992-02-26
AU5689490A (en) 1990-12-13
GR3019686T3 (en) 1996-07-31
RU2056421C1 (ru) 1996-03-20
EP0402989B1 (en) 1996-04-03
CN1025193C (zh) 1994-06-29
CN1047865A (zh) 1990-12-19
ATE136305T1 (de) 1996-04-15

Similar Documents

Publication Publication Date Title
KR910000714A (ko) 항진균성 4[4-[4-[4-[[2-(2,4-디플루오로페닐)-2-(1h-아졸릴메틸)-1,3-디옥솔란-4-일]메톡시]페닐]-1-피페라지닐]페닐]트리아졸론 및 이미다졸론
US4160838A (en) Antimicrobial and plant-growth-regulating triazole derivatives
US4079062A (en) Triazole derivatives
KR870007140A (ko) 살균활성을 갖는 아졸릴 유도체
FI97804C (fi) Menetelmä terapeuttisesti aktiivisten (substituoitu aralkyyli)triatsoli-, -imidatsoli-, -pyridiini- ja -pyrimidiiniyhdisteiden valmistamiseksi
CS203098B2 (en) Fungicide and agent for growth plants regulator and process for preparing efective compound
KR940005616A (ko) 아졸 화합물, 그의 제법 및 용도
KR920701174A (ko) 퀴나졸린-3-알카노산 유도체, 이의 염 및 이의 제조방법
IE840463L (en) Imidazoles and triazoles
FI89798B (fi) Framstaellning av 4-/4-/4-/4-//2-(2,4-difluorfenyl)-2-(1h-azolylmetyl)-1,3-dioxolan-4-yl/metoxi/fenyl/-1-piperazinyl/fenyl/triazoloner
SU703020A3 (ru) Способ получени гетероциклических производных 1-(1,3-диоксолан-2-илме-тил)-1н-имидазолов или -1н-1,2,4-триазолов или их кислотно-аддитивных солей,в виде смеси или отдельных стереоизомеров
KR860008173A (ko) 치환된 n-[(4-피페리딘일)알킬]비사이클축합 옥사졸아민 및 티아졸아민의 제조방법
KR890002055A (ko) 하이드록시알킬-아졸릴 유도체 및 이의 제조방법
FI75811C (fi) Foerfarande foer framstaellning av fungicida triazolderivat.
WO1996029325A1 (en) Homochiral compounds for the preparation of ketoconazole, terconazole and related antifungal drugs
EP0329711A1 (en) 2,4,4-tri- and 2,2,4,4-tetra substituted-1,3-dioxolane compounds
KR940021536A (ko) 1,3-비스(1,2,4-트리아졸-1-일)-프로판-2-올 유도체의 제조방법
EP0030371B1 (en) N-substituted imidazole derivatives, a process for their preparation, antifungal compositions comprising them and their use for preparing such compositions
CA2032237A1 (en) Azole compounds, their production and use
KR880011128A (ko) 1,5-디페닐 -1h-1,2,4-트라이졸 -3- 카르복시아미드 유도체 및 이를 함유하는 제초제 조성물
KR860004033A (ko) 광학적으로 활성인 아졸릴카르비놀 유도체, 즉 광학적으로 활성인 2-(4-클로로페녹시메틸)-3,3-디메틸-1-(1,2,4-트리아졸-1-일)-2-부탄올의 제조방법
KR900000358A (ko) 2,4 -디히드로- 3h-1,2,4-트리아졸-온 유도체
KR900000360A (ko) 2,4-디히드로-3h-1,2,4-트리아졸-온 유도체
KR970704705A (ko) 히드라지노 및 아미드라존 중간체를 사용하여 항진균성 아졸을 제조하는 방법(process for preparing an antifungal azole with hydrazino and amidrazone intermidiates)
KR940007005A (ko) 페닐이미다졸유도체, 이의 제조방법, 이를 포함하는 제초제 및 이 제초제의 사용법

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20030825

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040904

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040904